About Molnlycke Health Care
Molnlycke Health Care is a world-leading medical solutions company focused on providing single-use surgical and wound care products. The company offers a range of products including antiseptics, surgical drapes, staff clothing, surgical gloves, wound dressings, and operating room solutions designed to support healthcare professionals in patient care. Molnlycke Health Care primarily serves the healthcare industry, with products aimed at improving patient, clinical, and economic outcomes. It is based in Gothenburg, Sweden.
Molnlycke Health Care Patents
Molnlycke Health Care has filed 20 patents.
Medical dressings, Nursing, Traumatology, Team sports, Necrosis
Medical dressings, Nursing, Traumatology, Team sports, Necrosis
Latest Molnlycke Health Care News
Feb 12, 2024
The Global Negative Pressure Wound Therapy Market size is expected to reach $3.7 billion by 2030, rising at a market growth of 6.3% CAGR during the forecast period. Venous leg ulcers are often chronic and challenging to manage due to underlying venous insufficiency. NPWT provides a comprehensive approach to wound care by addressing the specific characteristics of venous leg ulcers, such as high exudate levels and delayed healing. Consequently, the venous leg ulcers segment would acquire nearly 13% of the total market share by 2030. NPWT facilitates granulation tissue formation in the wound bed, a critical aspect of healing venous leg ulcers. By creating a controlled environment, NPWT accelerates healthy tissue formation and contributes to overall wound closure. Outpatient care and home healthcare enhance accessibility and convenience for patients. NPWT devices that can be utilized in these settings allow patients to receive advanced wound care without prolonged hospital stays, contributing to a more patient-friendly experience. The shift towards outpatient care and home healthcare aligns with a patient-centric approach to healthcare. NPWT, with its focus on promoting patient comfort and improving outcomes, complements this approach and contributes to patient satisfaction. Thus, the market is expanding significantly due to the rapid shift towards outpatient care and home healthcare. Additionally, the escalating rates of diabetes globally contribute to the rising incidence of diabetic foot ulcers. NPWT has proven to be particularly effective in managing diabetic wounds, driving its adoption as a standard of care in many healthcare settings. Infections and complications that progress to more serious health problems are common in diabetic wounds. NPWT helps reduce the risk of complications by creating a sealed environment that minimizes the potential for infections, promoting a faster and more controlled healing process. Therefore, increasing prevalence of diabetes has been a pivotal factor in driving the growth of the market. Moreover, Disruptions in global supply chains resulted from the pandemic, which impacted the manufacturing and dissemination of medical devices, including NPWT systems and consumables. Manufacturers faced raw material shortages, transportation restrictions, and workforce disruptions. The prolonged nature of the pandemic, with lockdowns and restrictions affecting daily life, contributed to an increase in chronic wounds and pressure injuries. Patients, especially those at higher risk, experienced delays in seeking healthcare, leading to more complex wounds requiring advanced treatments like NPWT. Thus, the COVID-19 pandemic had a moderate effect on the market. However, the initial cost of NPWT devices can be relatively high. This cost factor may limit the adoption of NPWT, particularly in regions or healthcare systems with budget constraints. The affordability of these devices remains a significant challenge for widespread implementation. The high cost of NPWT devices can influence reimbursement policies and coverage decisions. Payers may hesitate to provide adequate reimbursement for NPWT procedures, limiting the financial support available for healthcare providers and patients. Thus, high cost of NPWT devices can slow down the growth of the market. By End-Use Analysis On the basis of end-use, the market is divided into hospitals, homecare, and others. The homecare segment garnered a significant revenue share in the market in 2022. Homecare is a patient-centered healthcare approach that provides treatment in the convenience and comfort of an individual's home. NPWT's application at homecare aligns with this trend, providing patients with a more personalized and less disruptive experience compared to inpatient care. NPWT in homecare settings enables the extended continuity of care. Patients recovering from surgery, managing chronic wounds, or undergoing post-acute care can continue their NPWT treatment seamlessly at home, contributing to better overall outcomes. By Product Analysis By product, the market is categorized into conventional NPWT and single-use NPWT. The single-use NPWT segment covered a considerable revenue share in the market in 2022. Single-use NPWT devices are often designed to be compact and portable, offering flexibility in terms of patient mobility. This is particularly advantageous in outpatient settings and home healthcare, where patients can continue their treatment conveniently. Single-use NPWT devices often use advanced dressing materials for optimal performance and comfort. These materials are selected to promote effective negative pressure, manage exudate, and create an environment conducive to wound healing. By Type Analysis Based on type, the market is classified into diabetic foot ulcers, venous leg ulcers, pressure ulcers, burn wounds, and others. The diabetic foot ulcers segment acquired a substantial revenue share in the market in 2022. Diabetic foot ulcers are often chronic and complex wounds that require specialized care. NPWT provides a comprehensive approach to wound management by promoting granulation tissue formation, reducing edema, and addressing the specific challenges associated with DFUs. DFUs can lead to severe complications, and in some cases, amputation may be necessary. The use of NPWT in treating diabetic foot ulcers has been associated with reduced amputation rates. This positive outcome benefits patients and contributes to the overall demand for NPWT. By Regional Analysis Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. The prevalence of chronic wounds, such as diabetic foot ulcers, pressure ulcers, and venous leg ulcers, is on the rise in North America. North America has a highly advanced healthcare infrastructure, including advanced medical facilities and a focus on adopting cutting-edge medical technologies. The aging population in North America, particularly in the United States, has led to a higher prevalence of chronic conditions such as diabetes. Key Companies Profiled
Molnlycke Health Care Frequently Asked Questions (FAQ)
Where is Molnlycke Health Care's headquarters?
Molnlycke Health Care's headquarters is located at Gamlestadsvagen 3C, Gothenburg.
What is Molnlycke Health Care's latest funding round?
Molnlycke Health Care's latest funding round is Acq - Fin - III.
Who are the investors of Molnlycke Health Care?
Investors of Molnlycke Health Care include Patricia Industries, Apex Venture Partners and Nordic Capital.
Who are Molnlycke Health Care's competitors?
Competitors of Molnlycke Health Care include NeoChord, OrthAlign, GENICON, Acelity, Nuvesse Skin Therapies and 7 more.
Compare Molnlycke Health Care to Competitors
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Mpathy specializes in diagnostic services within the healthcare sector. They offer end-to-end COVID-19 testing solutions designed to be accessible and easy to understand for individuals, communities, and organizations. The company primarily serves sectors that require regular and reliable COVID-19 testing services. It was founded in 2003 and is based in United Kingdom.
CryoPen is a company focused on the advancement of cryosurgery within the medical sector, providing a cryosurgical system designed for a variety of dermatological procedures. Their main product, the CryoPen Cryosurgical System, utilizes linear compression cooling technology to perform cryosurgery without the use of hazardous cryogenic gases or liquids, offering a safer and more precise alternative to traditional methods. The system is primarily used by healthcare professionals across multiple specialties, including general practice, obstetrics and gynecology, and dermatology, to treat skin lesions and pre-cancerous cervical lesions with minimal scarring and without the need for anesthetic. It was founded in 2005 and is based in Corpus Christi, Texas.
Novare Surgical Systems, Inc. develops atraumatic systems that aim to provide surgeons with unmatched confidence in and control of their surgical occlusion. With its engineered designs, the company aims to expand the surgical temporary occlusion markets of the U.S. and Europe, estimated to be worth up to $155 million each.
Cambridge Endoscopic Devices specializes in the development and manufacturing of medical instruments for endoscopic procedures within the healthcare sector. Their products are designed to support minimally invasive surgeries by providing tools that enable visualization and operation within the body without major incisions. It is based in Framingham, Massachusetts.
DERMING SRL is a private research institute focused on dermatological testing within the cosmetics and pharmaceutical sectors. The company conducts clinical evaluations on the tolerability and effectiveness of products designed for contact with skin, hair, nails, and external mucous membranes, and develops customized protocols for its clients. DERMING SRL primarily serves the cosmetics, cosmeceuticals, dietary supplements, and skin care product industries with its scientific testing services. It is based in Italy.